Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy

Journal of Clinical Virology

Volumn 73, Issue , 2015, Pages 64-69

  Kim, Ji Won ^a   Min, Chang Ki ^b   Mun, Yeung Chul ^c   Park, Yong ^d   Kim, Byung Soo ^d   Nam, Seung Hyun ^e   Koh, Youngil ^f,g   Kwon, Ji Hyun ^h   Choe, Pyoeng Gyun ^f   Park, Wan Beom ^f   Kim, Inho ^f,g  

^a Seoul National University Bundang Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ewha Womans University   (South Korea)

^d College of Medicine   (South Korea)

^e Veterans Health Service Medical Center   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Seoul National University   (South Korea)

^h Chungbuk National University Hospital   (South Korea)

Author keywords

Bortezomib; Enzyme linked immunospot assay; Herpes zoster; Multiple myeloma; Varicella zoster virus

Indexed keywords

ACICLOVIR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GAMMA INTERFERON; MELPHALAN; PREDNISOLONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; IFNG PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHUMAN; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; VARICELLA ZOSTER VIRUS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORTEZOMIB; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84949449433     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.10.018     Document Type: Article

References (21)

1. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005, 23:630-639.
2. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359:906-917.
3. Harousseau J.L., Attal M., Avet-Loiseau H., Marit G., Caillot D., Mohty M., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J. Clin. Oncol. 2010, 28:4621-4629.
4. Tong Y., Qian J., Li Y., Meng H., Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am. J. Hematol. 2007, 82:403-404.
5. Chanan-Khan A., Sonneveld P., Schuster M.W., Stadtmauer E.A., Facon T., Harousseau J.L., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J. Clin. Oncol. 2008, 26:4784-4790.
6. Kim S.J., Kim K., Kim B.S., Lee H.J., Kim H., Lee N.R., et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin. Lymphoma Myeloma 2008, 8:237-240.
7. Vickrey E., Allen S., Mehta J., Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009, 115:229-232.
8. Kim S.J., Kim K., Do Y.R., Bae S.H., Yang D.H., Lee J.J. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn. J. Clin. Oncol. 2011, 41:353-357.
9. Minarik J., Pika T., Bacovsky J., Langova K., Scudla V. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br. J. Haematol. 2012, 159:111-113.
10. Fukushima T., Sato T., Nakamura T., Iwao H., Nakajima A., Miki M., et al. Daily 500mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res. 2012, 32:5437-5440.
11. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., Carvajal-Vergara X., Mateos J., Vidriales B., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
12. Nencioni A., Schwarzenberg K., Brauer K.M., Schmidt S.M., Ballestrero A., Grunebach F., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
13. Smith J.G., Liu X., Kaufhold R.M., Clair J., Caulfield M.J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 2001, 8:871-879.
14. Sadaoka K., Okamoto S., Gomi Y., Tanimoto T., Ishikawa T., Yoshikawa T., et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J. Infect. 2008, 198:1327-1333.
15. Hambleton S., Gershon A.A. Preventing varicella-zoster disease. Clin. Microbiol. Rev. 2005, 18:70-80.
16. Morison W.L. Letter: herpes simplex and herpes zoster in neoplasia. Lancet 1974, 1:1293.
17. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp. Neurol. 2007, 204:317-325.
18. Focosi D. Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia. Clin. Lymphoma Myeloma 2009, 9:E16-E17.
19. Levin M.J., Oxman M.N., Zhang J.H., Johnson G.R., Stanley H., Hayward A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 2008, 197:825-835.
20. Distler E., Schnurer E., Wagner E., von Auer C., Plachter B., Wehler D., et al. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Biol. Blood Marrow Transplant. 2008, 14:1417-1424.
21. Gebo K.A., Kalyani R., Moore R.D., Polydefkis M.J. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J. Acquir. Immune Defic. Syndr. 2005, 40:169-174.